Predicting Therapeutic Response to Molecular Hydrogen in Autoimmune Diseases via Immunophenotyping.
Shan-Wen Lui, Ting-Yu Hsieh, Jeng-Wei Lu, Yi-Jung Ho, Feng-Cheng Liu · APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The study reports that HRPI shows potential as a predictive biomarker for MHAT efficacy and guides personalized autoimmune treatment.
What the Researchers Studied
Source-reported study description: 25 patients with autoimmune diseases; 15 untreated RA patients served as controls
What the Study Found
The authors reported: Among the 108 immune subsets analyzed, 15 exhibited significant changes, including 11 T cell and 4 B cell subsets.
The authors reported: Based on baseline immune profiles and the percent change in fatigue scores (assessed by the Brief Fatigue Inventory, BFI-T), a Hydrogen-assisted Treatment Response Prediction Index (HRPI) was developed, demonstrating strong predictive performance (ROC = 0.9375, p = 0.0118).
What the Findings Mean
The authors concluded/reported: HRPI shows potential as a predictive biomarker for MHAT efficacy and guides personalized autoimmune treatment.
Hydrogen Dose and Delivery
Normalized molecular-hydrogen equivalent: 8.50 mg H₂ from 170 mg hydrogen-enriched coral calcium using the H2HUBB 20:1 Ca-equivalent rule.
Study Details
Publication type: human_clinical_study
Evidence source level: B_ABSTRACT
Original scholarly source: https://pubmed.ncbi.nlm.nih.gov/40590161/